Hims & Hers Health, Inc.

Hims & Hers Health, Inc.

HIMSNYSE / NASDAQHealthcareSmall cap

$14.60-$1.42 (-8.9%)

Last close · Data as of Nov 20, 2026

Market cap
$6.5B
P/E
50.5x
EV / EBITDA
46.1x
Revenue
$2.3B
Net margin
5.5%
ROCE
6.0%

-56.6% over the last year

Hims & Hers Health, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-50.0%
3M
-54.2%
6M
-36.6%
1Y
-56.6%
5Y
+99.7%

52-week range

Day change -$1.42 (-8.9%) from $16 to $15 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HIMS, bought on each weekday since 2021.

News & filings

What Hims & Hers Health filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthRevenue grew 59.0% in fiscal 2025.

Concerns (1)

  • The price is 44.8% below its 200-day average.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.

Read moreShow less

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Sector
Healthcare
Shares outstanding
225.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.5B
P/E
50.5x
P/B
12.0x
EV / EBITDA
46.1x
EV / Sales
3.1x
P/S
2.8x
52-week high
$40.02
52-week low
$14.52

Profitability

Operating margin
4.5%
Net margin
5.5%
EBITDA margin
6.8%
ROE
23.7%
ROCE
6.0%
ROIC
7.4%
ROA
6.0%
Asset turnover
1.09

Growth

Revenue
$2.3B
Revenue growth, 1Y
59.0%
Revenue CAGR, 3Y
64.5%
Net profit growth, 1Y
1.8%
Free cash flow
$57.4M

Solvency

Current ratio
1.90
Debt / Equity
2.07
Debt / Assets
0.52
CFO / Net profit
2.34
Cash / Market cap
3.5%

Where the revenue went

Of every $100 of FY2025 revenue, $5 was left as net income.

Hims & Hers Health, Inc. income statement flow, FY2025
Hims & Hers Health, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$614.3M
RevenueGross profit$1.7B
Gross profitResearch and development$149.3M
Gross profitSelling, general and administrative$1.2B
Gross profitOther operating expenses$286.4M
Gross profitOperating income$105.6M
Operating incomePretax income$105.6M
Interest and other incomePretax income$18.3M
Pretax incomeNet income$123.9M
Tax benefit and otherNet income$4.4M

Revenue and net profit

Revenue grew 59.0% in FY2025; net profit is the dashed line.

Hims & Hers Health, Inc. revenue and net profit by fiscal year
Hims & Hers Health, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$526.9M-$65.7M
FY2023$872.0M-$23.5M
FY2024$1.5B$126.0M
FY2025$2.3B$128.4M

Cash flows

FY2025: $300.0M from operations, $57.4M free after investment (dashed).

Hims & Hers Health, Inc. operating and free cash flow by fiscal year
Hims & Hers Health, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$26.5M-$33.8M
FY2023$73.5M$47.0M
FY2024$251.1M$198.3M
FY2025$300.0M$57.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.3B+59.0%1Y
EBITDA
$160.1M+102.7%1Y
Net profit
$128.4M+1.8%1Y
Cash from operations
$300.0M+19.5%1Y
Free cash flow
$57.4M-71.1%1Y
Revenue CAGR, 3Y
64.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.3B$160.1M$128.4M$57.4M23.7%+59.0%+1.8%

Monthly returns

Month-by-month returns of HIMS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.2B
Liabilities$1.6B
Equity$540.9M
Paid-in capital$652.4M
Retained earnings-$113.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HIMS highlighted.

P/E against peers

HIMS trades at 50.5x earnings against a peer median of -26.8x.

  1. Hims & Hers Health, Inc. (this company)50.5x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc., Terns Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Hims & Hers Health, Inc.HIMSthis company$6.5B50.5x12.0x23.7%46.1x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Immunovant, Inc.IMVT$6.7B-13.3x7.9x-59.3%-10.9x
Lantheus Holdings, Inc.LNTH$6.7B28.7x6.1x21.4%17.2x
Kymera Therapeutics, Inc.KYMR$6.1B—3.9x-19.7%—
Terns Pharmaceuticals, Inc.TERN$6.1B-63.6x6.1x-9.6%-51.0x
Rhythm Pharmaceuticals, Inc.RYTM$6.0B—22.3x-74.8%—
Peer median—-26.8x7.7x-25.0%-23.7x

Year-to-date ROI

HIMS since 1 January, against earlier years.

Historical volatility

HIMS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Hims & Hers Health, Inc. operating margin by fiscal year
Hims & Hers Health, Inc. operating margin by fiscal year
DateOperating margin
FY2022-13.0%
FY2023-3.4%
FY20244.2%
FY20254.5%
LineFY2025
Cost of revenueCost Of Revenue$614.3M
Gross profitGross Profit$1.7B
Operating expensesOperating Expense$1.6B
Research and developmentResearch And Development$149.3M
Other operating expensesOther Operating Expenses$286.4M
Total expensesTotal Expenses$2.2B
Pretax incomePretax Income$123.9M

Learn while you research

Academy chapters picked for Hims & Hers Health, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 50.5, learn when high multiples are justified.6 min read
  3. 03 Growth Investing59% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Leverage RatiosDebt/Equity of 2.07 is elevated, understand what that means for solvency.6 min read
  5. 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  6. 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
Browse the full Equiscale Academy →